Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study

Moreau, Philippe; Mateos, Maria-Victoria; Berenson, James R.; Weisel, Katja; Lazzaro, Antonio; Song, Kevin; Dimopoulos, Meletios A.; Huang, Mei; Zahlten-Kumeli, Anita; Stewart, A. Keith

dc.contributor.author	Weisel, Katja
dc.date.accessioned	2019-09-03T10:25:49Z
dc.date.available	2019-09-03T10:25:49Z
dc.date.issued	2018
dc.identifier.issn	1474-5488
dc.identifier.uri	http://hdl.handle.net/10900/92291
dc.language.iso	en	de_DE
dc.publisher	Elsevier Science Inc	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/S1470-2045(18)30354-1	de_DE
dc.subject.ddc	610	de_DE
dc.title	Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190321153956_02084
utue.publikation.seiten	953-964	de_DE
utue.personen.roh	Moreau, Philippe
utue.personen.roh	Mateos, Maria-Victoria
utue.personen.roh	Berenson, James R.
utue.personen.roh	Weisel, Katja
utue.personen.roh	Lazzaro, Antonio
utue.personen.roh	Song, Kevin
utue.personen.roh	Dimopoulos, Meletios A.
utue.personen.roh	Huang, Mei
utue.personen.roh	Zahlten-Kumeli, Anita
utue.personen.roh	Stewart, A. Keith
dcterms.isPartOf.ZSTitelID	Lancet Oncology	de_DE
dcterms.isPartOf.ZS-Issue	7	de_DE
dcterms.isPartOf.ZS-Volume	19	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE